Posted On October 13, 2025 /
By Debbie Muse / Posted in Blog
Texas Retina Participating in New Phase III Clinical Trial for Uveal Melanoma
Under the leadership of principal investigator Timothy Fuller, MD, Texas Retina will soon begin enrolling patients in the OptimUM-10 clinical trial, a randomized, Phase III, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic
read more